



NEWS RELEASE

CareDx Shares Latest Clinical Data at the TTS 2020 Virtual Conference

2020-09-11

AlloSure and AlloSeq cfDNA surveillance tools to be featured along with four virtual symposia at international congress

SOUTH SAN FRANCISCO, Calif., Sept. 11, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced that it will share the latest clinical data on its AlloSure and AlloSeq cfDNA surveillance tools at the 28th International Congress of The Transplantation Society (TTS) scheduled to be held virtually from September 13th to September 16th, 2020. The company will host four industry symposia, showcase six posters, and sponsor the plenary sessions at TTS.

CareDx will host four virtual symposia on transplant care featuring the following speakers:

Sunday, September 13th, 2020, 10:00 PM EDT

- Ashraf Dada, MD, King Faisal Hospital, Jeddah – AlloSeq dd-cfDNA and Risk Prediction in Kidney Transplantation
- Stan Jordan, MD, Cedars Sinai – Clinical Utility of Non-invasive Molecular Biomarkers: Understanding Molecular Injury
- Shiang-Cheng Kung, MD, UCSF – Clinical Utility of AlloSure

Monday, September 14th, 2020, 6:00 AM EDT

- Jonathan Bromberg, MD, University of Maryland – AlloSure: A Guide to Understanding Molecular Injury in Transplant Allografts



- Georg Bohmig, MD, Medical University of Vienna – AlloSeq dd-cfDNA: Donor-derived Cell-free DNA for Organ Injury Detection
- Luciano Potena, MD, University of Bologna – dd-cfDNA as a Biomarker for Subclinical Acute Rejection in Heart Allograft Transplantation

Monday, September 14th, 2020, 1:00 PM EDT

- Nicolae Leca, MD, University of Washington – Resolution by AlloSure Differentiates Ambiguous Rejection
- Sanjiv Anand, MD, Intermountain Medical Center – Relative Change Value of AlloSure: Guidance for Clinical Care
- Keith Melancon, MD, George Washington University – The GW Clinical Experience: AlloSure Surveillance in Kidney Transplant Patients
- Nicole Ali, MD, NYU Langone Health - SARS-CoV-2 & Renal Transplantation: The NYU Langone Experience
- Arjang Djamali, MD, University of Wisconsin – AlloSure Case Studies from the University of Wisconsin

Tuesday, September 15th, 2020, 1:00 PM EDT

- Suphamai Bunnapradist, MD, UCLA – Relative Change Value of AlloSure: the DART Experience
- Sudhir Thaduri, MD, University of Alabama at Birmingham – Immunosurveillance with AlloSure Plus Donor Specific Antibody, an Alternative to Renal Allograft Biopsy
- Dhiren Kumar, MD, VCU Health – Resolution by AlloSure Differentiates Ambiguous Rejection
- Nicole Ali, MD NYU Langone Health – SARS-CoV-2 & Renal Transplantation: the NYU Langone Experience
- Matthew Cooper, MD, Georgetown MedStar – AlloSure Case Studies from MedStar Georgetown Hospital

Additionally, there are six posters on CareDx offerings presented during TTS:

- Jonathan Bromberg, MD, University of Maryland – Characterization of an Integrative Prognostic Score for US Patients Taken from the DART Study
- Eugene DePasquale, MD, Keck School of Medicine, USC – dd-cfDNA as a Risk Factor for Initiating De-novo Donor Specific Antibodies in Heart Transplantation
- Stan Jordan, MD, Cedars Sinai – The Use of dd-cfDNA as a Predictive Tool for Future Proteinuria
- Oyedolamu Olaitan, MD, Rush University – Use of dd-cfDNA as a Surrogate Marker of Injury Following Hypothermic Machine Profusion
- Anthony Langone, MD, Vanderbilt University – Value of dd-cfDNA when Considering Recipient Ethnicity to Further Help Risk Stratify Transplant Recipients
- Markus Wharmann, MD, Medical University of Vienna – Detection of donor-derived cell-free DNA: Non-invasive Prediction of Silent Antibody-mediated Rejection in Donor-specific Antibody-positive Renal Allograft Recipients

"It is critical to provide a continued education platform for the transplant community in this new virtual world. I am glad that CareDx is at the forefront of this endeavor through their leading participation at TTS, and look forward to some rewarding discussions and innovative talks during this virtual conference," said Dr. Stanley Jordan, Medical Director, Kidney Transplant Program at Cedars Sinai Medical Center.

"We look forward to presenting significant data at TTS this year and are taking a very active role in this important congress," said Peter Maag, CEO of CareDx. "CareDx continues to bring innovation to transplant medicine for patients and their caregivers."

About CareDx

CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

CONTACTS:

CareDx, Inc.

Sasha King

Chief Marketing Officer

415-287-2393

[sking@caredx.com](mailto:sking@ caredx.com)

Investor Relations

Greg Chodaczek

646-924-1769

investor@caredx.com

Source: CareDx, Inc.